Phase 2 Sickle Cell Disease Trial, Recruiting NCT06872333 Sponsor: Masonic Cancer Center, University of Minnesota Condition: Sickle Cell Disease
Back to Sickle Cell Disease

Phase 2 Sickle Cell Disease Trial, Recruiting

NCT06872333
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People diagnosed with Sickle Cell Disease (a blood disorder affecting red blood cells)
  • People with Sickle Cell Disease who have a fully matched brother or sister available as a donor — this applies regardless of how often or how severely symptoms occur
  • People with Transfusion-Dependent Alpha- or Beta-Thalassemia (a blood disorder requiring regular blood transfusions)
  • People diagnosed with Diamond Blackfan Anemia (a rare bone marrow disorder)
  • People with other non-cancerous blood disorders (confirm with trial site for specific conditions)
  • People whose general health and ability to function meets a minimum level on a standard medical scale — those below this level may still be considered based on the study team's review
  • People who are sexually active and could become pregnant, or whose partner could become pregnant, must agree to use a highly effective form of contraception during treatment and for at least 4 months after the transplant

Who may not be able to join:

  • People who are pregnant, breastfeeding, or planning to become pregnant during the study — those who could become pregnant must have had a negative pregnancy test within 30 days of starting treatment
  • People with HIV who have a detectable level of the virus in their blood — all HIV-positive candidates must be assessed by an infectious disease specialist with a management plan in place before transplant
  • People with an active infection that has not been responding to appropriate treatment (infections that are stable or improving after one week of treatment may still be eligible, or four weeks for fungal infections)
  • People with a known allergy to any of the components used in the study
  • People with a psychiatric illness or personal circumstances that, in the enrolling doctor's judgement, would make it difficult to follow the study requirements
  • People with any other health condition that, in the enrolling doctor's judgement, would make participation unsuitable

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 14 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: 612-626-2961

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
Masonic Cancer Center, University of Minnesota
Registry
ClinicalTrials.gov
Start date
19 November 2024
Est. completion
1 June 2030

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Incidence of Graft versus Host Disease (GvHD)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 14 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov